Publications

There have been numerous presentations and publications on our technology and on compounds developed using it. Publications related to our pipeline are published below.

Compound

Meeting

Title

Pivekimab Sunirine

Meeting

Title

ASH 2023

Pivekimab Sunirine, a CD123 CD123-Targeting Antibody Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

EHA 2023

Interim Analysis of a Registration Enabling Study of Pivekimab Sunirine, a CD123-Targeting Antibody-Drug Conjugate, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

ASCO 2023

Phase 1b/2 Study of Pivekimab Sunirine in Combination With Venetoclax/Azacitidine or Magrolimab for Patients With CD123-Positive Acute Myeloid Leukemia

ASH 2022

Broad Activity for the Pivekimab Sunirine, Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory and Frontline Acute Myeloid Leukemia

SOHO 2022

Pivekimab Sunirine Triplet with Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory AML and Reduced Infusion Related Reactions

ASH 2021

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

ASH 2021

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

ASH 2020

Combining IMGN632, a Novel CD123 Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax facilitates Apoptosis in vitro and Prolongs Survival in vivo in AML Models

ASH 2020

Clinical Profile of IMGN632, a Novel CD123 Targeting Antibody Drug Conjugate, in Patients with Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ASH 2020

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123 Positive Acute Myeloid Leukemia

ASCO 2020

A Phase 1/2 Study of IMGN632, a Novel CD123 Targeting Antibody Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123 Positive Hematologic Malignancies

ASCO 2020

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123 Positive Acute Myeloid Leukemia

ASH2019

Encouraging Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

ASH2019

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

ASH2019

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

ASH2019

A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123- Positive Hematologic Malignancies

EHA 2019

The Combination of IMGN632, a CD123-Targeting ADC, with Venetoclax Enhances Anti-Leukemic Activity In vitro and Prolongs Survival In vivo in Pre-Clinical Models of Human AML

ASH 2018

A Phase 1, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

EHA 2016

IMGN632: A Novel Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Potent DNA-Alkylator is Highly Active in Preclinical Models of AML with Poor Prognosis

ASH 2016

Oral Presentation: A CD123-Targeting Antibody Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow

ASH 2016

IMGN632: An Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Novel DNA-Alkylating Payload is Highly Active and Prolongs Survival in AML Xenograft Models

Mirvetuximab Soravtansine-gynx (ELAHERE™)
SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING

Meeting

Title

ESGO 2023

Efficacy of Mirvetuximab Soravtansine in Folate Receptor Alpha High, Platinum-Resistant Ovarian Cancer by Type and Number of Prior Treatment Regimens: An Exploratory Analysis

ASCO 2023

Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

ASCO 2023

GLORIOSA: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine with Bevacizumab vs. Bevacizumab as Maintenance in Platinum-Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer

SGO 2023

Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study

ESGO 2022

A Randomized Phase II Trial of Mirvetuximab Soravtansine in Folate Receptor Alpha High Recurrent Ovarian Cancer Eligible for Platinum-Based Chemotherapy

ESGO 2022

Characterization of Extended Treatment Benefit From Three Phase 1 and 3 Clinical Trials Examining Patients With Folate Receptor Alpha–Positive Recurrent Ovarian Cancer Treated With Single-Agent Mirvetuximab Soravtansine

IGCS 2022

Mirvetuximab Soravtansine and Bevacizumab in Folate Receptor Alpha-Positive Ovarian Cancer: Efficacy in Patients With and Without Prior Bevacizumab

IGCS 2022

Mirvetuximab Soravtansine and Carboplatin for Treatment of Patients With Recurrent Folate Receptor Alpha–Positive Platinum-Sensitive Ovarian Cancer: A Final Analysis

IGCS 2022

Clinical Benefit of Mirvetuximab Soravtansine in Ovarian Cancer Patients With High Folate Receptor Alpha Expression: Results From the SORAYA Study

IGCS 2022

PICCOLO: An Open-Label, Single-Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian Cancers With High Folate Receptor Alpha Expression

ESMO 2022

Analyses of Patient-Reported Outcomes with Mirvetuximab Soravtansine Versus Standard Chemotherapy in the Randomized Phase 3 FORWARD I Study in Ovarian Cancer (GOG 3011)

ESMO 2022

Population Pharmacokinetic Analysis of Mirvetuximab Soravtansine in Patients With Folate Receptor α–Positive Cancer

ESMO 2022

Exposure Response Analysis for Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Folate Receptor α-Positive Cancer

ASCO 2022

Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Characterization of Anti-Tumor Activity in the SORAYA Study

ASCO 2022

Integrated Safety Summary of Single-Agent Mirvetuximab Soravtansine in Patients with Folate Receptor α Positive Recurrent Ovarian Cancer: Phase I and III Clinical Trials

SGO 2022

Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study

SGO 2022

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody-Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis

SGO 2022

PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent, Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression

SGO 2022

MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression

ASCO 2021

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum Agnostic Ovarian Cancer: Final Analysis

ESMO 2020

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: final results from a Phase 1b study in patients (pts) with ovarian cancer

ASCO 2020

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum Agnostic Ovarian Cancer

ASCO 2020

GOG 3045/ENGOT OV55/MIRASOL: A Randomized, Open Label, Phase 3 Study of Mirvetuximab Soravtansine versus Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Alpha Receptor Expression

ESMO 2019

FORWARD I (GOG 3011): A Phase III Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate, Versus Chemotherapy in Patients with Platinum-resistant Ovarian Cancer

ESMO 2019

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Carboplatin and Bevacizumab: Initial results from a Phase 1b Study in Patients (pts) with Ovarian Cancer

ASCO 2019

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab in Patients (pts) with Platinum-resistant Ovarian Cancer: Final Analyses from the FORWARD II Study

ESMO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), with Pembrolizumab in Platinum-Resistant Ovarian Cancer (PROC): Initial Results of an Expansion Cohort from FORWARD II, a Phase Ib Study

ASCO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer: Maturing Safety and Activity Profile from the FORWARD II Phase 1b Study

SGO 2018

Initial Safety and Activity Findings from a Phase IB Escalation Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC) in Combination with Pembrolizumab in Platinum-Resistant Epithelial Ovarian Cancer Patients

SGO 2017

Characterization of Folate Receptor Alpha (FRα) Expression in Archival Tumor and Biopsy Samples in a Phase I Study of Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), in Relapsed Epithelial Ovarian Cancer Patients

ASCO 2017

Safety Findings from FORWARD II: a Phase IB Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), Mirvetuximab Soravtansine (IMGN853), in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin (PLD), or Pembrolizumab in Patients with Ovarian Cancer

ASCO 2017

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), in Platinum-Resistant Epithelial Ovarian Cancer (EOC) Patients: Activity and Safety Analyses in Phase I Pooled Expansion Cohorts

SITC 2016

Treatment of Tumor Cells with Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), Activates Monocytes Through Fc-FcyR Interaction and Immunogenic Cell Death

ASCO 2016

IMGN853 (Mirvetuximab Soravtansine), a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC): Single Agent Activity in Platinum-Resistant Ovarian Cancer (EOC) Patients

AACR 2015

Preclinical Evaluation of Mirvetuximab Soravtansine (IMGN853) Combination Therapy in Ovarian Cancer Xenograft Models

AACR 2015

Development and Application of an Immunohistochemistry-Based Clinical Assay for Evaluating Folate Receptor Alpha (FRα) Expression in the Clinical Setting

IMGN151

Meeting

Title

AACR 2020

IMGN151: A Next Generation Folate Receptor Alpha Targeting Antibody-Drug Conjugate Active Against Tumors with Low, Medium, and High Receptor Expression

IMGC936

Meeting

Title

AACR 2021

IMGC936, an Investigational ADAM9-Targeting Antibody-Drug Conjugate, is Active Against Patient-Derived ADAM9-Expressing Xenograft Models

AACR 2019

IMGC936, a First-in-Class ADAM9-Targeting Antibody-Drug Conjugate, Demonstrates Promising Anti-Tumor Activity

Early Pipeline

Meeting

Title

AACR 2019 Posters

ImmunoGen’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.

Our Products

Our Pipeline

Our Science

Our Target Indications